Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
29060/ 449 (A)	16	108	2	55	0.4%	4.07 [0.97, 17.09]
29060/ 449 (B)	23	112	3	55	0.6%	3.76 [1.18, 12.00]
29060/448 (A)	16	106	6	51	1.0%	1.28 [0.53, 3.08]
29060/448 (B)	9	106	5	52	0.7%	0.88 [0.31, 2.50]
29060/785 (A)	19	103	3	27	0.6%	1.66 [0.53, 5.20]
29060/785 (B)	10	96	3	26	0.5%	0.90 [0.27, 3.04]
29060/785 (C)	20	107	3	26	0.6%	1.62 [0.52, 5.04]
29060/785 (D)	11	100	2	26	0.4%	1.43 [0.34, 6.06]
Ball et al (2014)	20	79	8	79	1.4%	2.50 [1.17, 5.34]
Bose 2008	14	130	7	134	1.0%	2.06 [0.86, 4.94]
Burke et al. (A) 2002	10	119	7	122	0.9%	1.46 [0.58, 3.72]
Burke et al. (B) 2002	9	125	7	122	0.9%	1.25 [0.48, 3.26]
Burke et al. (C) 2002	10	125	7	122	0.9%	1.39 [0.55, 3.54]
Byerley et al. 1988	19	32	13	29	3.2%	1.32 [0.81, 2.17]
Cassano et al. 1986	8	161	10	149	1.0%	0.74 [0.30, 1.83]
Claghorn 1992a	7	36	5	35	0.7%	1.36 [0.48, 3.89]
Claghorn et al. 1996	11	47	5	46	0.8%	2.15 [0.81, 5.71]
Cohn et al. 1985	14	54	10	58	1.5%	1.50 [0.73, 3.10]
Cohn et al. 1991	10	40	6	40	1.0%	1.67 [0.67, 4.15]
Coleman et al. 1999	19	115	19	121	2.3%	1.05 [0.59, 1.88]
Coleman et al. 2001	22	154	22	152	2.7%	0.99 [0.57, 1.71]
Croft et al. 1999	16	118	14	119	1.8%	1.15 [0.59, 2.25]
Dominguez et al. 1985	5	33	6	31	0.7%	0.78 [0.27, 2.31]
Doogan et al. 1994	2	99	1	101	0.1%	2.04 [0.19, 22.14]
Dubé et al. 2009	4	62	6	138	0.5%	1.48 [0.43, 5.07]
Dunbar et al. 1991	53	240	38	249	5.6%	1.45 [0.99, 2.11]
Edwards et al. 1993	0	21	1	20	0.1%	0.32 [0.01, 7.38]
Fabre 1992	8	39	3	38	0.5%	2.60 [0.74, 9.06]
Fabre et al. 1995	33	278	9	91	1.6%	1.20 [0.60, 2.41]
Fabre et al. 1996	8	46	6	44	0.8%	1.28 [0.48, 3.38]
Fava et al. 2005	6	47	4	43	0.6%	1.37 [0.42, 4.54]
Feighner et al. 1989a	14	51	5	48	0.9%	2.64 [1.03, 6.76]
Feighner et al. 1989b	5	31	4	19	0.6%	0.77 [0.23, 2.50]
Feighner et al. 1999	83	521	8	129	1.6%	2.57 [1.28, 5.17]
Goldstein et al (2002)	7	33	12	70	1.1%	1.24 [0.54, 2.85]
Goldstein et al, 2004	7	87	3	89	0.5%	2.39 [0.64, 8.93]
Griebel et al. 2012 a	6	84	4	75	0.5%	1.34 [0.39, 4.56]
Griebel et al. 2012 b	5	80	4	77	0.5%	1.20 [0.34, 4.31]
Higuchi et al. (A) 2011	7	161	3	86	0.5%	1.25 [0.33, 4.70]
Higuchi et al. (B) 2011	5	83	4	86	0.5%	1.30 [0.36, 4.66]
Itil et al. 1983	11	22	5	22	1.0%	2.20 [0.92, 5.29]
Kasper (A) 2005	1	173	1	90	0.1%	0.52 [0.03, 8.22]
Kasper (B) 2005	4	164	0	90	0.1%	4.96 [0.27, 91.16]
Kasper et al. 1995	30	110	30	110	4.3%	1.00 [0.65, 1.54]
Kiev 1992	7	38	1	40	0.2%	7.37 [0.95, 57.11]
Learned et al. 2012	16	166	4	156	0.7%	3.76 [1.28, 11.00]
Lepola et al. (A) 2003	7	155	1	77	0.2%	3.48 [0.44, 27.76]
Lepola et al. (B) 2003	12	160	1	77	0.2%	5.78 [0.76, 43.61]
LVM-MD-06	9	79	6	93	0.8%	1.77 [0.66, 4.75]
Lydiard et al. 1997	22	132	14	129	2.0%	1.54 [0.82, 2.87]
Mao et al (2015)	2	19	0	18	0.1%	4.75 [0.24, 92.65]
Muijen et al. 1988	0	26	1	28	0.1%	0.36 [0.02, 8.42]
MY-1043/BRL-029060/115 (A)	43	284	2	59	0.4%	4.47 [1.11, 17.93]
MY-1043/BRL-029060/115 (B)	29	289	2	59	0.4%	2.96 [0.73, 12.07]
MY-1045/BRL-029060/1 (PAR128) (A)	60	357	5	70	1.0%	2.35 [0.98, 5.65]
MY-1045/BRL-029060/1 (PAR128) (B)	27	351	5	70	0.9%	1.08 [0.43, 2.70]
NCT00668525 (A)	23	322	4	109	0.7%	1.95 [0.69, 5.50]
NCT00668525 (B)	28	324	3	109	0.6%	3.14 [0.97, 10.12]
NCT01020799	3	50	9	99	0.5%	0.66 [0.19, 2.33]
NCT01473381	18	282	14	281	1.7%	1.28 [0.65, 2.53]
Nemeroff et al. 2007	16	104	15	102	1.9%	1.05 [0.55, 2.00]
Nierenberg et al (2007)	30	274	15	137	2.3%	1.00 [0.56, 1.79]
Norton et al. 1984	13	35	11	25	2.1%	0.84 [0.46, 1.57]
Olie et al.1997	8	129	5	129	0.7%	1.60 [0.54, 4.76]
PAR 29060.07.001	1	13	1	12	0.1%	0.92 [0.06, 13.18]
Perahia et al (2006)	3	97	1	99	0.2%	3.06 [0.32, 28.93]
Peselow et al. 1989a	12	40	10	42	1.5%	1.26 [0.61, 2.59]
Rapaport (A) 2008	14	164	10	89	1.3%	0.76 [0.35, 1.64]
Rapaport (B) 2008	22	173	11	89	1.7%	1.03 [0.52, 2.03]
Ratti et al. 2011	14	120	5	120	0.8%	2.80 [1.04, 7.53]
Reimherr et al. 1990	46	149	28	150	4.7%	1.65 [1.10, 2.50]
Rickels et al. 1992	10	55	8	56	1.1%	1.27 [0.54, 2.98]
Roose 2004	6	87	12	90	0.9%	0.52 [0.20, 1.32]
Schatzberg 2006	6	100	15	96	1.0%	0.38 [0.16, 0.95]
Schneider 2003	29	371	23	376	2.9%	1.28 [0.75, 2.17]
SCT-MD 02 (A) 2002	13	125	7	64	1.1%	0.95 [0.40, 2.27]
SCT-MD 02 (B) 2002	8	123	8	63	0.9%	0.51 [0.20, 1.30]
SCT-MD-13	14	132	7	135	1.0%	2.05 [0.85, 4.91]
SCT-MD-26	17	154	10	155	1.4%	1.71 [0.81, 3.62]
SCT-MD-27 (A)	19	136	7	67	1.2%	1.34 [0.59, 3.02]
SCT-MD-27 (B)	21	138	8	68	1.4%	1.29 [0.60, 2.77]
SCT-MD-35	11	138	7	135	0.9%	1.54 [0.61, 3.85]
Sheehan et al. 2009	24	99	9	95	1.6%	2.56 [1.25, 5.22]
Shrivastava et al. 1992	2	40	4	40	0.3%	0.50 [0.10, 2.58]
Silverstone et al. 1999	22	121	14	119	2.1%	1.55 [0.83, 2.87]
Smith et al.1992	5	39	0	38	0.1%	10.72 [0.61, 187.51]
Wakelin 1986	8	32	3	14	0.6%	1.17 [0.36, 3.75]
Wang et al 2014	22	156	13	155	1.9%	1.68 [0.88, 3.22]
WELL AK130926	18	149	17	137	2.1%	0.97 [0.52, 1.81]
WELL AK130927	19	138	13	141	1.8%	1.49 [0.77, 2.90]
Total (95% CI)		**11303**		**7904**	**100.0%**	**1.37 [1.25, 1.49]**
Total events	1376		693			

Heterogeneity: Tau² = 0.00; Chi² = 87.03, df = 89 (P = 0.54); I² = 0%
Test for overall effect: Z = 6.85 (P < 0.00001)